IQOS Passes Marlboro, the Smoke-Free Engine Accelerates, and the Stock Has Come Back to Us — Upgrading to Outperform on a ~20% Pullback

Results vs. Consensus

Q1 2026 Scorecard

Segment Scorecard (first quarter under the new structure)

Quality of Beat/Miss

Revenue: Group organic growth of +2.7% is the softest of the coverage period and landed roughly in line with (a hair below the higher marks of) consensus. But the composition is the point: International Smoke-Free grew +15.8% organic while the U.S. fell -31.6% organic on inventory normalization and International Combustibles was flat (+1.0%) on a -5.1% volume comp. Strip the pre-flagged U.S. drag and the underlying growth is healthy. The soft headline is a mix-and-comparison artifact, not a demand signal.

Margins & OI: Gross margin expanded (gross profit +3.8% organic on +2.7% organic revenue), but organic OI grew only +0.9% as management invested and absorbed the U.S. segment loss. This was explicitly guided as the softest quarter of 2026, with broadly flat organic net revenue and OI, so the weak OI optics are on-plan rather than a negative surprise. International Smoke-Free gross margin above 70% remains the structural story.

EPS: Adjusted EPS of $1.96 (+16.0%) beat, but +5.3% ex-currency reflects a $0.18 FX tailwind doing much of the work, consistent with the below-algorithm 2026 shape. Reported EPS of $1.56 fell 9.3% on a non-cash fair-value adjustment of PMI's India minority stake, an accounting item excluded from adjusted results and not a business event. The quality of the underlying beat is solid but modest once FX is removed.

Segment Performance

International Smoke-Free — The Engine Accelerates

The segment that is now ~two-thirds of PMI's value delivered its cleanest quarter in the coverage period: net revenue +24.7% (+15.8% organic) on +11.9% volume growth, gross profit +28.6% (+19.4% organic), and a gross margin above 70%. IQOS is the driver, with HTU adjusted IMS +10.9% (broad-based, with TEREA, DELIA/SENTIA and LEVIA all contributing) and shipment growth +11.3%. Excluding Japanese consumer pantry-loading ahead of the April 1 excise, adjusted IMS still grew ~9.4%. Outside Europe and Japan, adjusted IMS grew +19.4%, and Taiwan reached ~6% national offtake share (8% in Taipei) just months after launch, which management called its most successful major launch to date. VEEV crossed one billion equivalent units of quarterly shipments for the first time (+94.8%) and now shares the #1 closed-pod position in Europe.

"IQOS surpassed Marlboro and became the #1 nicotine brand in markets where present, gaining 1.7pp to reach 10.9% of combined cigarette and HTU industry volumes." — PMI Q1 2026 press release

Assessment: This is the strongest affirmation of the bull case in the coverage period. A 70%+ gross margin, ~77% category share, double-digit IMS, and IQOS overtaking Marlboro together say the smoke-free franchise is compounding at scale with best-in-class economics. The margin is still being harvested (management flagged ~3% smoke-free price increases plus ongoing supply-chain productivity), and volume maximization remains the priority given IQOS's ~2x dollar-per-unit advantage over combustibles.

U.S. — The First Standalone Look Is Ugly, and Mostly Pre-Flagged

The new U.S. segment's debut disclosure was weak on every line: net revenue -30.8% (-31.6% organic), gross profit -44.5%, and an operating loss. The cause is ZYN shipments falling 23.5% to 155 million cans (2.3 billion pouches), reflecting the channel-inventory normalization management flagged in February (against a ~160 million-can underlying Q1'25 base) plus a demanding promotional comparison (H1 2025 was abnormally under-promoted). Nielsen offtake decelerated to +10% for the quarter, and management acknowledged the most recent weeks running ~5–6%. ZYN still leads with a premium position, but management was candid that it lacks access to the higher-strength and broader-flavor segments driving the most category dynamism.

"ZYN offtake volumes grew by 10%, notwithstanding an uneven competitive landscape where we do not yet have access to all of the most dynamic strength and flavor segments... we are preparing to launch innovations in the coming months, including ZYN Ultra, which remains under active FDA review." — PMI Q1 2026 press release

Assessment: The optics are alarming, the substance is more nuanced. The revenue and shipment collapse is a comparison-and-inventory phenomenon that management pre-announced, and the underlying quarterly shipment base (~740–750M annualized) is intact. What is genuinely concerning is the offtake deceleration to +10% (and ~5–6% recently) against a category still growing double digits, which confirms ZYN is ceding share of growth while it waits on ZYN Ultra to close the higher-strength portfolio gap. This is the single biggest risk in the print and the reason our conviction is moderate rather than high. Management expects a H2 improvement on easier comps plus innovation; that is plausible but FDA-dependent.

International Combustibles — Pricing +8.5%, Marlboro Record Q1

Combustibles delivered net revenue +6.8% (+1.0% organic) on pricing of +8.5%, with gross profit +9.8% (+3.9% organic), despite a -5.1% volume decline lapping a strong prior-year comparison. Marlboro gained 0.4pp to a record first-quarter category share of 10.7%, though overall PMI cigarette share slipped 0.6pp to 24.8% on unfavorable market mix and lower share in Indonesia, Russia and Turkey. For 2026, management guides combustible pricing to ~+6% and a cigarette volume decline of ~3%, with India and Mexico excise shocks weighing.

Assessment: The combustible cash engine performed to spec: strong pricing more than offsetting volume declines, generating the gross-profit growth that funds the smoke-free investment and the dividend. The -5.1% volume is a comparison artifact rather than accelerating structural decline. No concerns here.

IQOS by Geography

Key Topics & Management Commentary

Overall Management Tone: Confident on the international smoke-free momentum and refreshingly candid on the U.S. Management opened by saying performance "exceeded our expectations" on IQOS strength, and spent much of the Q&A defending the ZYN thesis with a clear-eyed acknowledgment of the higher-strength portfolio gap and a specific (if FDA-gated) recovery path. The posture was that of a company whose core is firing and whose one problem child (U.S. ZYN growth) is well-understood and being addressed, rather than one masking a broad deterioration.

1. IQOS Passes Marlboro: The Milestone

The headline development is symbolic and substantive at once: IQOS overtook Marlboro to become PMI's #1 nicotine brand by volume in markets where both are present, reaching 10.9% of combined cigarette and HTU industry volumes. IQOS is now a $10 billion-plus brand holding ~77% of the global heat-not-burn category, a share it has sustained near 75% for five to six years despite intensifying competition.

"I don't think you have any equivalent in the smoke-free space in the world to IQOS, this multibillion-dollar brand, much north of $10 billion. This is a brand that has consistently owned around 75% of the category, which for an innovation is really unusual." — Jacek Olczak, Group CEO

Assessment: The milestone matters beyond the headline. It marks the point at which PMI's smoke-free flagship has structurally eclipsed the cigarette that defined the company, which is precisely the mix-shift the entire bull case rests on. Combined with a 70%+ segment gross margin, it is the strongest single data point for the "this is no longer a tobacco stock" argument.

2. The First Look Under the New Segments

Q1 2026 is the first quarter reported under PMI's new structure: International Smoke-Free, International Combustibles, and U.S. The change delivers what we most wanted, a standalone view of the U.S. (ZYN) economics, and the debut was a study in contrasts: International Smoke-Free at +15.8% organic revenue with 70%+ gross margins, the U.S. at a loss on an inventory-driven revenue collapse.

Assessment: Strategically, the transparency is a positive even when the first U.S. print is ugly, because it lets the market underwrite ZYN's economics directly. The Q1 U.S. loss is not representative of steady-state ZYN margins (management continues to describe them as best-in-class above the IQOS average); it reflects a quarter in which shipments fell 23.5% while fixed U.S. investment continued. As the inventory comparison normalizes through 2026, the segment's underlying profitability should re-emerge in the reported numbers.

3. International Smoke-Free Accelerates to +15.8% Organic

Covered in Segment Performance, but it anchors the upgrade. The core engine did not merely hold; it accelerated, with organic revenue growth of +15.8% and organic gross-profit growth of +19.4%, IQOS IMS double-digit and broad-based, and margins above 70%. This is the part of PMI that justifies the premium multiple, and it is compounding faster, not slower.

Assessment: The acceleration is the reason the soft group organic OI (+0.9%) does not worry us: the value-driving segment is firing, and the group softness is concentrated in the pre-flagged U.S. comparison. Own the segment that is accelerating; watch the segment that is normalizing.

4. ZYN's Portfolio Gap and the ZYN Ultra Catalyst

Management was unusually direct that ZYN's offtake deceleration (to +10%, ~5–6% recently) reflects a specific portfolio gap: the most dynamic parts of the U.S. category are higher-nicotine-strength and broader-flavor products, where ZYN currently has nothing above 6mg. ZYN Ultra (higher strength, additional flavors) is in active FDA pilot review, and management said it has launch readiness "essentially as we speak," hoping for a summer decision while declining to forecast the agency.

"We are in the 5%, 6% growth range, talking about the last week. Our expectation is that ZYN Ultra is going to come with a proposal matching areas of strong dynamism in the U.S. nicotine pouch market, and we expect it to bring renewed momentum to the ZYN brand in the coming months." — Jacek Olczak, Group CEO

Assessment: This is the crux of the U.S. risk. The good news: the deceleration has an identified, addressable cause and a specific fix already in FDA review, and management noted the FDA authorized a competitor's higher-nicotine product in December, suggesting no categorical regulatory barrier. The bad news: FDA timing is unforecastable, and every quarter of delay lets competitors entrench in the higher-strength segment. It is optionality, not certainty, which is exactly why we upgrade at ~19x rather than pay up for it.

5. Japan: Pantry-Loading and the April 1 Excise

Japan reported IMS +10.4% (a record 34.9% total-nicotine share, +2.7pp), but the figure was inflated by consumer pantry-loading ahead of the April 1 heated-tobacco excise increase; excluding that, IMS grew ~5.9%. The heat-not-burn category reached ~53% of national nicotine offtake. Management said it is too early (roughly two weeks post-increase) to read the post-excise trend but sees nothing contradicting its confidence in continued long-term category growth, while flagging a Q2 reversal of the Q1 pantry-loading and a second excise increase in October.

"There is nothing in what we see in the first days that would contradict our confidence in the continuation, on the long term, of strong growth of the category and the success of IQOS in Japan. But let's look at what the disruption will be in Q2." — Jacek Olczak, Group CEO

Assessment: The biggest 2026 headwind produced a manageable Q1 distortion rather than a demand shock, which is reassuring. The real test is Q2 (pantry-load reversal) and the October second step. Underlying Japan IMS of ~5.9% ex-pantry is healthy for a market this mature, and the record share amid intensifying competition is the durability signal that matters. Japan is a 2026 volatility source, not a thesis threat.

6. Europe: Flavor-Ban Optics Mask ~8% Underlying

Europe IMS of +5.4% looked soft versus its historical high-single-to-low-double-digit pace, but management attributed the shortfall to the Poland characterizing-flavor ban (implemented in January) and ongoing Ukraine disruption; excluding the flavor-ban markets, adjusted IMS grew ~8%. Italy returned to strong double-digit growth (share above 20% in key cities), replicating the recovery path seen in other markets after flavor bands wash through.

Assessment: The Europe deceleration is a known, temporary regulatory artifact, not a demand problem, and the Italy recovery is the template for how Poland normalizes over the coming quarters. Underlying European momentum (~8% ex-ban) is intact.

7. Combustible Resilience and the U.S. Pouch Excise Watch

Combustible pricing of +8.5% and a record Q1 Marlboro share reaffirmed the cash-engine model. Separately, management addressed reported state-level proposals (e.g., New York) to raise excise taxes on nicotine pouches, arguing such taxes are counterproductive given pouches' position on the risk continuum and the FDA's own stance, while cautioning that U.S. states act independently and the situation is speculative.

Assessment: Combustibles remain the reliable half of the story. State-level pouch excise is a new, low-probability U.S. tail risk to monitor: it would raise consumer prices and reshape the promotional landscape, but it is not a 2026 model driver.

8. Guidance Held (Currency-Only Update) and the Middle East

Management reaffirmed the 2026 adjusted-EPS guide at $8.36–$8.51 (from $8.38–$8.53), characterizing the change as "currency only," with the ex-currency guide (+7.5–9.5%) unchanged and the organic revenue (5–7%) and OI (7–9%) frames intact. Q2 adjusted EPS is guided to $2.02–$2.07. On the Middle East conflict, management reported a small Q1 impact (Global Travel Retail and certain regional shipments) and some energy-cost pressure, without assuming a prolonged effect.

Assessment: Holding the operational guide after a soft-by-design Q1 is a quiet positive: the below-algorithm 2026 shape is stable, not deteriorating. That the update was "currency only" tells investors nothing in the underlying plan changed, which is exactly what a market braced for a cut needed to hear, and part of why the stock rallied.

Guidance & Outlook

The single most important thing about the guide is that it did not move on an operational basis. After a Q1 in which group organic OI grew just +0.9% and the U.S. segment swung to a loss, management held the full-year ex-currency EPS range and every underlying frame, updating only the currency line. For a stock that had fallen ~20% partly on fear the below-algorithm 2026 would be cut further, "nothing changed except FX" is a meaningfully positive message.

The H2 recovery is the crux of the 2026 case. Management expects a materially better U.S. ZYN dynamic in the second half on three drivers it laid out: easier shipment and revenue-per-can comparisons (H1 2025 had reloading and abnormally low promotion; Q3 2025 carried the one-off free-can drag that will not repeat), plus new innovation (ZYN Ultra) landing "in the coming months." The Q2 guide of $2.02–$2.07 embeds continued U.S. softness before that H2 inflection.

Guidance style: Consistent and, this quarter, reassuring. PMI is managing a well-telegraphed digestion year and, one quarter in, is delivering to plan on the international engine while the U.S. plays out as pre-flagged. The reaffirmation is the tell that the trough thesis is on track.

Analyst Q&A Highlights

International Smoke-Free Margin Priority and the U.S. ZYN Price Gap

The opening exchange paired a question on whether harvesting international smoke-free gross margins (now above 70%) is a priority with one on the widening U.S. ZYN price premium versus competition. Management prioritized volume over margin internationally and reaffirmed ZYN's premium positioning in the U.S.

Q: "Your international smoke-free gross margins are over 70%, very impressive. How much of a priority is harvesting further margin? And on U.S. ZYN, your price gaps have widened back out, has there been any strategic change in the trade-off between pricing and market share?"
— Eric Serotta, Morgan Stanley

A: "On international smoke-free margin, that's not the top priority, because on IQOS we already benefit from higher margin than combustible and more than 2x the dollar per unit. Maximizing volume is a big objective. On ZYN in the U.S., the premium versus competition remains roughly the same; it is a moving target. ZYN is the leader, it will remain the more premium brand, and we will navigate the parameters, including pricing, to achieve that."
— Jacek Olczak, Group CEO

Assessment: The volume-over-margin priority internationally is the right call for a share-gaining franchise with a 2x per-unit economic advantage, and it means the 70%+ margin is a floor being reinvested into growth, not a peak. On ZYN, management is holding premium positioning rather than chasing share with price, which protects margin but concedes some volume growth to lower-priced competition until ZYN Ultra arrives.

Confidence in the H2 U.S. ZYN Recovery and Launching Without FDA

A question sought the basis for management's expected H2 ZYN improvement and probed whether PMI would consider rolling out innovation ahead of FDA authorization, given the agency's slow reviews.

Q: "You expect ZYN U.S. performance to improve over the year, what gives you confidence? How much short-term profitability are you willing to sacrifice for volume? And given the FDA's failure to fast-track reviews, would you consider rolling out innovation without approval?"
— Bonnie Herzog, Goldman Sachs

A: "Q2 still faces a tough comparison, last year had reloading and almost no promotion, so an abnormally high revenue per can. In H2 the comparison normalizes, and Q3 last year had the one-off free-can operation that hurt our financials and won't repeat. And we expect innovation in the coming months to positively impact the second half. On approval, there is a process in the U.S. and we follow it diligently."
— Jacek Olczak, Group CEO

Assessment: The H2 recovery rests on comparison mechanics (which are certain) plus innovation timing (which is not). Management pointedly declined to launch ahead of the FDA, which is the responsible and brand-protective choice but also means the ZYN Ultra catalyst is entirely gated by an agency PMI cannot control. The comparison tailwind is bankable; the innovation tailwind is hope.

Drivers of the IQOS Beat and Margin Trajectory

A question asked what specifically drove the better-than-expected IQOS performance, whether any Q1 timing benefits would reverse, and the key drivers of ongoing IQOS profitability growth.

Q: "Your Q1 came in better than expected, driven by IQOS. Can you give more color on the drivers, clarify any timing benefits that might reverse, and explain the key drivers of IQOS profitability growth, pricing versus productivity?"
— Bonnie Herzog, Goldman Sachs

A: "The biggest driver is IQOS itself, a $10 billion-plus brand owning ~75% of the category, which is really unusual for an innovation. Italy back to strong double-digit growth illustrates it; Taiwan reaching 6% share in a few months shows the brand's pull. On margin, it's price, we're raising prices on IQOS and consumables in a number of markets, plus supply-chain and device-cost efficiency."
— Jacek Olczak, Group CEO

Assessment: The IQOS strength is broad-based (Italy recovery, Taiwan launch, new-market momentum) rather than a single timing item, which supports its durability. The margin algorithm, price plus productivity on a franchise that already earns 2x combustible per unit, is exactly the compounding structure that underpins the premium multiple. Management flagged a Q1 Japan pantry-load benefit reversing in Q2, but the underlying IMS ex-pantry (+9.4% group) is genuinely strong.

Whether ZYN Ultra Can Reaccelerate a Decelerating ZYN

A pointed question noted that extrapolating current Nielsen trends, ZYN volume could soon turn flat or negative absent ZYN Ultra, and asked what gives management confidence the higher-strength product can reaccelerate growth.

Q: "Extrapolating the current ZYN volume trend, it might soon become flattish or declining absent ZYN Ultra, and the FDA timing is not in your control. What gives you confidence ZYN Ultra can reaccelerate growth, and is the innovation timing dependent on the FDA process?"
— Pallav Mittal, Barclays

A: "We're around 5–6% growth in the last week. ZYN Ultra is a great product that will come with a proposal matching the areas of strong dynamism in the U.S. pouch market today, higher strength, more flavors, and we expect it to bring renewed momentum in the coming months. On innovation timing, there is a process in the U.S. and we follow it diligently."
— Jacek Olczak, Group CEO

Assessment: The most important admission in the Q&A, and the honest core of the U.S. risk. Management did not dispute that ZYN could go flat-to-negative without Ultra; it staked the reacceleration on a product whose timing it cannot control. This is why we upgrade on valuation and the international engine rather than on the U.S., ZYN Ultra is upside optionality we are not paying full price for, not a modelable near-term driver.

Early Japan Post-Excise Trends and the Corporate-Expense Swing

A question asked for early reads on Japan after the April 1 excise increase and, separately, for an explanation of a notable year-on-year decline in corporate expenses.

Q: "Can you tell us about the early trends in Japan after the April 1 excise increase? And on the significant year-on-year decline in corporate expenses, what is it attributable to and will it persist?"
— Andrei Andon-Ionita, Jefferies

A: "On Japan, it was only a fortnight ago, too early to say, but nothing in the first days contradicts our confidence in continued long-term category growth. On corporate expenses, it's largely technical, currency and transactional losses booked there in Q1'25 make the comparison look favorable. It's a Q1 event; we don't expect the rest of the year to differ much year-on-year."
— Jacek Olczak, Group CEO

Assessment: Both answers are appropriately deflationary. Management is not over-reading two weeks of Japan data, and it flagged the corporate-expense favorability as a non-recurring optical benefit rather than a structural improvement. The candor on the corporate-expense swing (a low-quality contributor to the Q1 beat) is the kind of transparency that builds credibility.

U.S. Pouch Category Moderation and ZYN Ultra Regulatory Risk

A question probed why U.S. nicotine-pouch category volume growth has moderated in recent scanner data and how management thinks about regulatory concerns around ZYN Ultra's higher strengths and broader flavors.

Q: "U.S. nicotine pouch volume growth has moderated over the past three to six months, what's driving it? And how do you think about potential regulatory concerns around higher nicotine strengths and a broad flavor range with ZYN Ultra?"
— Analyst, UBS

A: "Some of the newcomers to the category are coming with a lower average daily consumption, which may explain a slight softening. On regulation, the FDA authorized another product in December with higher nicotine content than ZYN has today, so if they had an issue with flavor and higher strength, I doubt they would have authorized it a few months ago."
— Jacek Olczak, Group CEO

Assessment: The category-moderation explanation (lower-consumption new users) is plausible and not alarming, and the December competitor authorization is a genuinely useful precedent that de-risks the ZYN Ultra regulatory path somewhat. It supports the view that the FDA gate is a timing question, not a categorical rejection risk, which is the more benign of the two possible reads on the U.S. situation.

What They're NOT Saying

1. A firm ZYN Ultra FDA date, or a plan B if it slips past 2026. Management hopes for "summer" and says it has launch readiness, but the entire H2 U.S. reacceleration depends on an agency decision it explicitly will not forecast, with no articulated contingency if the timeline slips.
2. The steady-state U.S. segment margin. The new segment debuted with a loss, and management reiterated "best-in-class margin" as a characterization without quantifying what normalized U.S./ZYN profitability looks like once the inventory comparison clears.
3. The post-pantry-load Japan trajectory. Management would not read the two weeks of post-April-1 data and deferred the October second-step impact ("too early to say"), leaving the biggest 2026 headwind's magnitude unquantified through at least Q2.
4. How much of the ZYN offtake deceleration is structural share loss versus timing. Management framed it as a portfolio gap plus lower new-user consumption, but did not disclose whether ZYN is losing existing users to higher-strength competitors, the distinction that determines whether ZYN Ultra recovers lost ground or merely adds new.
5. Any update on IQOS ILUMA U.S. The other long-deferred FDA catalyst went essentially unmentioned, consistent with the February position that the three-year algorithm does not lean on it.

Market Reaction

• Pre-print setup (April 21 close): $153.25, down ~4.5% year-to-date and ~6.6% over the trailing twelve months, near the 52-week closing low of $144.33. The stock had fallen ~20% from the ~$183 February high on Japan-excise and U.S.-ZYN concerns, so it entered the print oversold and under-owned.
• Reaction session (April 22): Gapped up ~3% at the open ($157.85), traded to $164.70 intraday, and closed at $163.95, up 7.0% (+$10.70).
• Relative move: The S&P 500 rose 1.0% on the session, so PM outperformed the tape by ~6 points, a strong idiosyncratic move.
• Volume: 7.7M shares versus a 4.8M 30-day average (1.6x), a conviction move off a low base rather than a blow-off.

The 7% rally on a quarter with +0.9% group organic OI and a U.S. segment loss tells you everything about positioning and expectations. The stock had been sold down ~20% in anticipation of exactly the weakness that materialized in the U.S., so the print carried little incremental bad news, and the accelerating international engine plus the IQOS-passes-Marlboro milestone plus a held guide were the positive surprises against a low bar. When a stock rallies hard on a mixed print, it is because the mix was better than feared and the price had already discounted the bad half.

For the rating, the reaction is the confirmation of our re-entry thesis. We downgraded in February at ~$183 into a full valuation and a guided deceleration; the market delivered the ~20% correction, resetting the multiple to ~19x, and the marginal buyer is now re-engaging on the international-smoke-free strength. We are buying the transformation back at a materially better price than we sold it.

Street Perspective

Debate: Does the IQOS-Passes-Marlboro Milestone Change the Multiple?

Bull view: IQOS overtaking Marlboro, with a 70%+ segment gross margin and ~77% category share, is the definitive proof PMI is a smoke-free consumer platform, not a tobacco company. That re-frames the multiple debate: a low-teens-growth, high-margin, share-gaining nicotine platform deserves a premium CPG multiple, and the new U.S. segment disclosure will surface ZYN economics that support it.

Bear view: Milestones are narrative, not numbers. The multiple is set by growth and risk, and 2026 EPS growth is below algorithm, the U.S. is losing share of category growth, and ESG constraints cap the buyer base regardless of what IQOS passes. A symbolic milestone does not re-rate a stock that just posted +0.9% organic OI.

Our take: Bull, with nuance. The milestone is not itself a catalyst, but it is a durable confirmation of the mix-shift thesis, and it lands as the international engine accelerates. It supports holding the premium multiple through a digestion year, which, at a de-rated ~19x, is enough for Outperform.

Debate: Is U.S. ZYN's Deceleration a Comparison Artifact or Structural Share Loss?

Bull view: The shipment collapse is pure inventory normalization (pre-flagged), and the offtake deceleration is a portfolio gap that ZYN Ultra, already in FDA review with launch readiness, will close in H2. ZYN still leads at 61.5% volume and 67% value share; the December price increase shows pricing power; the December competitor authorization de-risks the FDA path.

Bear view: Offtake at +10% (and ~5–6% recently) against a double-digit category is real share-of-growth loss, and management conceded ZYN could go flat-to-negative without Ultra, whose FDA timing is unknowable. Every quarter of delay entrenches higher-strength competitors, and the U.S. was supposed to be the second growth leg.

Our take: Split, and it is the key watch item. The shipment number is a non-issue (inventory); the offtake deceleration is a genuine concern. We lean cautiously bull because the cause is identified and the fix is in review, but we would downgrade again if offtake keeps sliding and ZYN Ultra slips materially past 2026. This is why conviction is moderate.

Debate: Valuation After the ~20% Pullback

Bull view: At ~$164 and ~19x the 2026 EPS midpoint with a ~3.6% growing yield, PMI has de-rated meaningfully into an accelerating international franchise and a held guide. On 2027 EPS (algorithm resuming), it trades ~17x. The pullback restored the cushion, and the international momentum plus 2026-trough setup argue for owning the recovery.

Bear view: Nineteen times is still a premium for a stock guiding below its own algorithm with a decelerating U.S. business and unresolved FDA and Japan-excise overhangs. The +7% pop already recaptured part of the discount, and a stock can stay cheap-ish and range-bound through a digestion year.

Our take: Bull. This is the mirror image of our February downgrade: we sold a re-rated franchise into a deceleration at ~21.6x; we buy a de-rated one into an accelerating core at ~19x. The valuation reset is the specific trigger we set, and it has been met.

Model & Valuation Framework

Valuation: At $163.95 and a 2026 adjusted-EPS midpoint of ~$8.435, PMI trades at ~19.4x forward earnings with a ~3.6% dividend yield, versus ~21.6x at our February downgrade. The stock has de-rated ~2 turns while the international smoke-free engine accelerated to +15.8% organic. On a forward 2027 EPS of ~$9.30 (algorithm resuming), PM trades at ~17.6x, a level at which a low-double-digit compounder with a growing ~3.6% yield offers a compelling total-return algorithm.

12-month price target framework: Base case ~$185–200 (roughly 22–23x our ~$8.65 blended NTM EPS, a modest multiple recovery toward the February level as the U.S. inventory comparison clears and the international engine compounds), implying ~13–22% upside plus the ~3.6% yield. Bull case ~$215–230 (25x if ZYN Ultra clears the FDA in 2026 and the market prices the 2027 re-acceleration early). Bear case ~$140–150 (17x if ZYN offtake keeps sliding, ZYN Ultra slips well past 2026, or Japan post-excise elasticity disappoints). The up-to-down skew from $164 is now favorable (~+22% bull / ~-11% bear), which supports the upgrade to Outperform.

Thesis Scorecard Post-Earnings

We grade the standing thesis carried since February. The core smoke-free pillars strengthened, the valuation bear point eased on the pullback (driving the upgrade), and the ZYN pillar is the one that weakened and now anchors our watch list.

Overall: Thesis strengthened on the core, weakened on the U.S. The two smoke-free bull pillars that drive most of PMI's value both strengthened (International SF accelerating, IQOS passing Marlboro), the valuation bear point eased sharply on the ~20% pullback, and the 2026-cadence concern is materializing exactly as pre-flagged with the guide held. The one genuine deterioration is ZYN's U.S. offtake, which becomes the dominant watch item.

Action: Upgrade to Outperform from Hold. This is the mirror of the February call and completes a disciplined round-trip: we harvested the re-rated franchise at the highs and re-engage the de-rated one into an accelerating core at ~19x. Conviction is moderate, held back by the U.S./ZYN deceleration. Downgrade-to-Hold triggers: ZYN offtake continuing to slide toward flat with ZYN Ultra slipping materially past 2026, OR the stock re-rating back toward ~22x without the U.S. inflecting. We would consider Underperform only on a genuine international-smoke-free stumble (an IQOS IMS break or a Japan post-excise demand shock), which is not in the data.

Bottom Line: We Sold the Highs, We Buy the Pullback

Q1 2026 crystallized both halves of the Philip Morris story. The half that drives the value, international smoke-free, accelerated to +15.8% organic revenue growth at a 70%+ gross margin, and IQOS crossed a genuine threshold by overtaking Marlboro as PMI's number-one nicotine brand. The half that carries the risk, U.S. ZYN, posted an ugly standalone debut, a segment operating loss on a shipment collapse and an offtake deceleration that management candidly tied to a higher-strength portfolio gap it cannot close until the FDA acts.

What tips the balance to an upgrade is not the print alone but the price. We downgraded in February at ~$183 and ~21.6x precisely because a fully-valued stock was heading into a guided digestion year. The market obliged, selling PMI down ~20% to the ~$153 area near its 52-week low, and in doing so handed back the ~18–19x re-entry we said would move us. The Q1 print then confirmed the core engine is accelerating, not decelerating, and that the below-algorithm 2026 guide is holding rather than cracking. That combination, a de-rated multiple plus an accelerating franchise plus a held guide, is the definition of the setup we upgrade into.

We are upgrading to Outperform, with conviction deliberately moderate. The U.S./ZYN deceleration is real and is the one number that could send us back to Hold, so we watch it closely and treat ZYN Ultra as upside optionality rather than a modeled driver. But at ~19x with the international smoke-free engine compounding at 15%-plus, IQOS now the leading nicotine brand, a ~3.6% growing yield, and 2026 shaping up as the trough before a 2027 re-acceleration, the risk/reward has flipped back to favorable. We sold the transformation at the highs; we are happy to own it again here.